ArticleCureus2026
Use of Glucarpidase for Methotrexate-Induced Nephrotoxicity During the Treatment of Primary Central Nervous System Lymphoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-dose methotrexate (HD-MTX)-based combination chemotherapy remains the mainstay of treatment for primary central nervous system lymphoma (PCNSL). However, MTX-induced nephrotoxicity can occur even with adequate preventive and supportive measures. We report a case of MTX-induced acute kidney injury (AKI) that developed during treatment for PCNSL. During the second course of chemotherapy, serum creatinine increased from 0.74 mg/dL at baseline to 2.15 mg/dL on day 3, accompanied by a peak plasma MTX concentration of 3.89 μmol/L. Following administration of glucarpidase, plasma MTX levels declined to 0.08 μmol/L by day 12, and renal function subsequently improved, with serum creatinine decreasing to 1.47 mg/dL by day 19. This biochemical improvement allowed continuation of MTX-based chemotherapy, and the patient ultimately achieved complete remission after seven courses of treatment. This case highlights the role of glucarpidase in facilitating treatment continuity in the setting of MTX-induced nephrotoxicity and underscores the importance of prompt and appropriate supportive care in the management of PCNSL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.